Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Total Payout Yield % : 0.26 (As of May. 15, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Clinuvel Pharmaceuticals's current Total Payout Yield % is 0.26%.

Clinuvel Pharmaceuticals Total Payout Yield % Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Total Payout Yield % Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Payout Yield %

Get a 7-Day Free Trial

0.06

0.10

0.09

0.18

0.22

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Payout Yield %	Get a 7-Day Free Trial															0.18	-	0.39	-	0.63

Competitive Comparison of Clinuvel Pharmaceuticals's Total Payout Yield %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Total Payout Yield % falls into.

Clinuvel Pharmaceuticals Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Clinuvel Pharmaceuticals's Total Payout Yield % for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	-1.326)	/	592.9236
	=	0.22%

Clinuvel Pharmaceuticals's annualized Total Payout Yield % for the quarter that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0	+	-1.653)	*	2	/	527.339196
	=	0.63%

Clinuvel Pharmaceuticals Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Clinuvel Pharmaceuticals Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.